ArticleTranslational lung cancer research2016
Comparison of methods for circulating cell-free DNA isolation using blood from cancer patients: impact on biomarker testing.
Article in Translational lung cancer research, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 72 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
72 citing papers in PubMed, 4 syntheses or guidelines pooled it, 135 citations in OpenAlex.
- Circulating Tumor DNA as a Biomarker for Precision Medicine in Prostate Cancer: A Systematic Review.International journal of molecular sciences · 2025Pooled it
- Clinical Practice Guideline for Blood-based Circulating Tumor DNA Assays.Annals of laboratory medicine · 2024Guideline
- Clinical Practice Guidelines for Pre-Analytical Procedures of Plasma Epidermal Growth Factor Receptor Variant Testing.Annals of laboratory medicine · 2022Guideline
- Guidelines for pre-analytical conditions for assessing the methylation of circulating cell-free DNA.Clinical epigenetics · 2021Pooled it
- Exploring the Predictive Value of Circulating Cell-Free DNA Within a Multiparameter Panel for Hepatocellular Carcinoma Detection.Life (Basel, Switzerland) · 2026Article
- Article
- Article
- Genomics and Epigenomics Approaches for the Quantification of Circulating Tumor DNA in Liquid Biopsy: Relevance of a Multimodal Strategy.International journal of molecular sciences · 2025Review
- Design, Development, and Clinical Validation of a Novel Kit for Cell-Free DNA Extraction.Diagnostics (Basel, Switzerland) · 2025Article
- Article
- Evaluation of automatic cell free DNA extraction metrics using different blood collection tubes.Scientific reports · 2025Article
- Circulating tumour DNA as a promising biomarker for breast cancer diagnosis & treatment monitoring.The Indian journal of medical research · 2025Review
- Extracted Plasma Cell-Free DNA Concentrations Are Elevated in Colic Patients with Systemic Inflammation.Veterinary sciences · 2024Article
- Optimizing ctDNA: An Updated Review of a Promising Clinical Tool for the Management of Uveal Melanoma.Cancers · 2024Review
- Investigation of Extracted Plasma Cell-Free DNA as a Biomarker in Foals with Sepsis.Veterinary sciences · 2024Article
- Circulating Nucleic Acids in Colorectal Cancer: Diagnostic and Prognostic Value.Disease markers · 2024Review
- Circulating tumour DNA in colorectal cancer management.The British journal of surgery · 2023Article
- New, fast and cheap prediction tests for BRCA1 gene mutations identification in clinical samples.Scientific reports · 2023Article
- Circulating DNA fragmentomics and cancer screening.Cell genomics · 2023Review
- A novel platform using homobifunctional hydrazide for enrichment and isolation of urinary circulating RNAs.Bioengineering & translational medicine · 2023Article
12 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe implementation of liquid biopsy for biomarker testing and response to treatment monitoring in cancer patients would presumable increase laboratory throughput, requiring the development of automated methods for circulating free DNA (cfDNA) isolation.
methodsThe present study compares the MagNA Pure Compact (MPC) Nucleic Acid Isolation Kit I and Maxwell
resultsFirstly, we observed that MPC method significantly extracted less cfDNA than MR (P<0.0001). However, there were no significant differences in extraction yields of QCNA and MR kits. cfDNA isolation yield was also associated with tumor stage but not with tumor location. Secondly, an oligonucleosomal DNA ladder pattern was observed in 88% of the samples and significant differences in the recovery of mono-, di- and tri-nucleosomes DNA fragments were observed between MPC and MR methodologies. Finally, tumor mutation quantification on cfDNA was performed on 38 paired samples using digital PCR. Mutant allele fractions (MAFs) between paired samples were not significantly different.
conclusionsMethods for isolation of cfDNA can affect DNA yield and molecular weight fractions recovery. These observations should be taken into account for cfDNA analysis in routine clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.